Rangering i aksjer
#23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Aksjekurs
$3.78
Sist synkronisert: 2026-08-21
Handel MaaT Pharma S.A. (MAAT)
Pris MAAT pris med markedsverdi på B
Markedsverdi av MaaT Pharma S.A.(MAAT)
Markedsverdi: $71.20M
Per August 2026 har MaaT Pharma S.A. en markedsverdi på $71.20M. Dette gjør MaaT Pharma S.A. til det 23616th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for MaaT Pharma S.A. fra 2021 til 2026
MAAT sammenlignet med topp 5 mest populære stocks
| Pris på MAAT |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.211T
|
+7,318,865.32%
|
|
|
|
|
$4.547T
|
+6,385,453.75%
|
|
|
|
|
$4.162T
|
+5,845,776.17%
|
|
|
|
|
$3.593T
|
+5,045,697.23%
|
|
|
|
|
$2.793T
|
+3,922,248.30%
|
